Price to sales forward of Adaptive Biotechnologies Corp. – HAM:1HM
This article displays the "Price to sales forward" financial metric for Adaptive Biotechnologies Corp. (HAM:1HM) as listed on the Hamburg Stock Exchange. The current market status is closed, with no trades observed. The data is provided by ICE Data Services and FactSet Research Systems Inc.
ETFs Investing in Adaptive Biotechnologies Corp. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Adaptive Biotechnologies Corp. (1HM), traded on the Frankfurt Stock Exchange. The ETFs are sorted by their market value of the Adaptive Biotechnologies Corp. shares they hold, providing details such as issuer, management style, expense ratio, assets under management (AUM), price, change, and 3-year NAV total return. The ETFs predominantly fall into small-cap and healthcare/biotechnology categories, with BlackRock, ARK Invest, and The Vanguard Group among the prominent issuers.
ADPT - Adaptive Biotechnologies Corp Earnings
This article provides a comprehensive financial overview of Adaptive Biotechnologies Corp (ADPT), detailing its stock performance, key financial metrics, and earnings information. It highlights the company's recent earnings surprise, insider and institutional ownership, and various profitability and efficiency ratios. The data presented covers market capitalization, sales, EPS, and short interest, alongside price performance over different periods.
Harlan Robins sells 116,160 ADPT shares (ADPT) per Form 144 filing
Harlan Robins, an insider at Adaptive Biotechnologies Corp (ADPT), filed a Form 144 disclosing the proposed and recent sales of 116,160 shares of Common Stock. This filing details sales on three separate occasions in the past three months, with values totaling over $1.9 million. It also lists the acquisition of shares through Restricted Stock Units and Performance Awards dating back to 2021.
Francis Lo plans ADPT share sales (NASDAQ: ADPT) under Form 144
Francis Lo has filed a Form 144 to report proposed dispositions of Adaptive Biotechnologies Corp (ADPT) common stock. The filing details an exercise of stock options for 179,039 shares and a grant of 20,221 Restricted Stock Units, along with two prior 10b5-1 sales totaling over $1 million. This document indicates planned insider sales and recent trading activity without specifying the cash-flow treatment or recipient of proceeds.
ADPT (NASDAQ: ADPT) insider sold shares via 10b5-1 plan in June 2026
An insider at Adaptive Biotechnologies Corp (NASDAQ: ADPT), Susan Bobulsky, executed three 10b5-1 sales in June 2026, totaling 21,000 shares with combined proceeds of $395,500. These routine transactions were filed via Form 144 and do not indicate new material information about the company. The filing also noted 487 Restricted Stock Units awarded to Bobulsky on March 4, 2022.
Adaptive biotechnologies CCO Sharon Benzeno sells over $3.5m in stock
Sharon Benzeno, CCO of Adaptive Biotechnologies Corp, sold over $3.5 million worth of company stock in late June through a pre-arranged trading plan. These sales followed the exercise of stock options worth approximately $885,555. The company recently reported strong Q1 2026 revenues and plans to separate its MRD and Immune Medicine units, with BTIG reiterating a Buy rating.
Adaptive Biotechnologies (ADPT) CCO trades shares under 10b5-1 plan
Sharon Benzeno, Chief Commercial Officer for Immune Medicine at Adaptive Biotechnologies (ADPT), exercised stock options and sold a total of 165,802 shares in open-market transactions on June 26 and 29, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, involved weighted-average sale prices of $21.00 and $21.14 per share. Following these sales, Benzeno directly holds 221,278 shares of ADPT common stock.
Form 4 Adaptive Biotechnologies Corp For: 30 June By Investing.com
This article reports on the filing of Form 4 for Adaptive Biotechnologies Corp for the period ending June 30. It focuses solely on this regulatory filing, indicating an insider transaction or change in ownership that companies are required to disclose. The article is very brief, providing the company name and the date of the filing, along with its stock symbol ADPT.
Form 4 Adaptive Biotechnologies Corp For: 29 June By Investing.com
This article reports on a Form 4 filing for Adaptive Biotechnologies Corp (ADPT) for activity on June 29. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their stock ownership. The article indicates a 0.23% increase in ADPT's stock price.
Adaptive Biotechnologies (ADPT) CCO sells 5,000 shares under 10b5-1 plan
Adaptive Biotechnologies' Chief Commercial Officer for MRD, Susan Bobulsky, sold 5,000 shares of common stock at $20.50 per share, totaling $102,500. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Bobulsky directly holds 406,775 shares of ADPT.
Adaptive Biotechnologies director Michelle Griffin sells $1.05m stock By Investing.com
Adaptive Biotechnologies Director Michelle Renee Griffin sold 52,084 shares of common stock for over $1 million, executed under a pre-arranged trading plan after exercising stock options. This sale occurred while the stock was trading near its 52-week high, following an 81.5% surge in the past year. The company recently reported strong Q1 2026 revenues, plans to separate its MRD and Immune Medicine units, and will offer $250 million in convertible senior notes.
Form 4 Adaptive Biotechnologies Corp For: 29 June By Investing.com
This article announces the filing of Form 4 for Adaptive Biotechnologies Corp on June 29. It is a brief news item from Investing.com, typical of filings news. The article also provides various market data and related news not directly tied to the Form 4 announcement.
Director at Adaptive Biotechnologies (NASDAQ: ADPT) exercises options and sells shares
Adaptive Biotechnologies (NASDAQ: ADPT) director Michelle Renee Griffin exercised stock options to acquire 52,084 shares at $7.80 per share and subsequently sold all of them for a weighted-average price of $20.18 per share on June 25, 2026. These transactions, valued at over $1 million, were conducted under a pre-arranged Rule 10b5-1 trading plan established in November 2025. Following the sale, Griffin retains 15,625 shares of Common Stock in the company.
Insider sells shares under 10b5-1 plan — ADPT (NASDAQ: ADPT)
Sharon Benzeno of Adaptive Biotechnologies Corp (ADPT) filed a Form 144 notice disclosing proposed sales tied to the exercise of stock options for 101,458 shares and Restricted Stock Units for 51,473 shares. The filing also reported a completed 10b5-1 sale of 11,034 shares on June 26, 2026, for $231,716.21. The document indicates 160,044,392 shares outstanding as of June 29, 2026.
ADPT Maintained by Guggenheim -- Price Target Raised to $22.00
Guggenheim has maintained a 'Buy' rating for Adaptive Biotechnologies (ADPT), raising the price target to $22.00. Despite this positive analyst outlook, GuruFocus indicates the stock is 106.7% overvalued based on its GF Value™, and insider activity shows significant selling, suggesting caution for potential investors. The company, which specializes in medical diagnostics, shows strong growth potential but struggles with profitability and valuation.
Price to sales forward of Adaptive Biotechnologies Corp. – SWB:1HM
This article displays the "price to sales forward" metric for Adaptive Biotechnologies Corp. (SWB:1HM) on the Stuttgart Stock Exchange. It indicates that there are no current trades and shows the value and change percentages for this financial metric over an unspecified period.
Price to book forward of Adaptive Biotechnologies Corp. – SWB:1HM
This article provides the "Price to book forward" financial metric for Adaptive Biotechnologies Corp. (1HM) on the Stuttgart Stock Exchange. It indicates that the market was closed at the time of publication and no trades were recorded for the stock. The information is presented within the TradingView platform, which offers various market data and analysis tools.
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)
BTIG has reiterated a Buy rating for Adaptive Biotechnologies (ADPT) with a $22 price target, citing the company's upsized convertible notes offering and plans to separate its MRD and immune medicine businesses. The firm views these strategic moves positively, particularly the spin-off of the immune medicine unit, as a way to unlock greater value in the core MRD business. Despite a slight dip in shares, BTIG remains confident in Adaptive's position of strength and momentum.
Adaptive Biotechnologies Corp. Actuals & Estimates (NASDAQ:ADPT)
This article provides an overview of Adaptive Biotechnologies Corporation (ADPT) stock, including its current price, historical performance, and analyst forecasts. It also details financial information such as market capitalization, recent earnings, revenue, and future earnings estimates. The company's volatility, employee count, and EBITDA are also discussed, along with guidance on how to trade its stock.
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)
BTIG has reiterated its Buy rating on Adaptive Biotechnologies (ADPT) with a $22 price target, following two major company announcements. The company upsized its convertible notes offering to $300 million and plans to separate its MRD and immune medicine businesses, a move BTIG believes will unlock value in the core MRD segment. Despite a slight dip in shares due to technicalities, BTIG remains confident in Adaptive Biotechnologies' strong momentum across all MRD applications.
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD By Investing.com
Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $20.82, reflecting a 70.95% increase over the past year. Despite this strong performance and impressive revenue growth of 55.87%, InvestingPro analysis suggests the stock is overvalued and is not expected to be profitable this year. The company recently reported better-than-forecast Q1 2026 revenue, a $250 million convertible senior notes offering, and plans to separate its MRD and Immune Medicine units.
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD By Investing.com
Adaptive Biotechnologies (ADPT) stock has reached a new 52-week high of $20.82, showing a 70.95% increase over the past year and a market capitalization of $3.31 billion. Despite strong revenue growth of 55.87% over the last twelve months, the company is not expected to be profitable this year, and the RSI indicates its stock is overbought. Recent financial performance includes first-quarter 2026 revenue of $70.9 million, a $300 million convertible senior notes offering, and plans to separate its MRD and Immune Medicine units by the end of 2026.
[144] Adaptive Biotechnologies Corp SEC Filing
This article details a Form 144 SEC filing by Adaptive Biotechnologies Corp (ADPT). The filing, submitted on June 26, 2026, concerns a proposed sale of securities by an issuer, indicating an exercise of stock options. The filing specifies the class of securities as Common, the broker as Morgan Stanley Smith Barney LLC, and the aggregate market value of shares to be sold as $260,637.75.
1HM Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Adaptive Biotechnologies Corp. (1HM) stock on the Hamburg Stock Exchange. It includes analyst ratings, future price estimates, historical price data, and financial information such as earnings, revenue, and EBITDA. The company's next earnings report is expected on August 5, 2026.
Adaptive Biotechnologies Corp. Actuals & Estimates (FWB:1HM)
This article provides an overview of Adaptive Biotechnologies Corp. (FWB:1HM) financials and analyst estimates. It details the company's stock ticker, analyst price forecasts, historical stock prices, and upcoming earnings report dates. The report also includes recent earnings per share, revenue, net income, EBITDA, and employee count.
[144] Adaptive Biotechnologies Corp SEC Filing
Adaptive Biotechnologies Corp (ADPT) has filed a Form 144, indicating a proposed sale of 5,000 common shares originating from stock options exercised on January 25, 2022. The filing also discloses recent 10b5-1 sales by Susan Bobulsky, totaling 16,000 shares for $293,000 on June 4 and June 11, 2026. Experts view these as routine insider sales and a regulatory filing, without significant impact on the company's operational or financial results.
[144] Adaptive Biotechnologies Corp SEC Filing
This article details a Form 144 SEC filing by Adaptive Biotechnologies Corp (ADPT) on June 25, 2026. The filing indicates a notice of proposed sale of securities, specifically 52,084 common shares with an aggregate market value of $1,007,304.56, acquired through the exercise of stock options. The securities are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
Adaptive Biotechnologies (Nasdaq: ADPT) sells $345M 0% notes and repays OrbiMed deal
Adaptive Biotechnologies has issued $345 million in 0% Convertible Senior Notes due 2031 through a private offering, generating net proceeds of $334.5 million. The company utilized a significant portion of these funds, $156.9 million, to fully repay its revenue interest obligations under the OrbiMed Purchase Agreement. This strategic financial move also involved repurchasing 1,451,800 shares of common stock and funding capped call transactions to mitigate potential dilution, with remaining proceeds allocated for general corporate purposes and initiatives in its minimal residual disease (MRD) business.
Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC Filing
Adaptive Biotechnologies Corp has announced the issuance of $345 million in 0% Convertible Senior Notes due in 2031. This information was disclosed in an SEC filing. The company's stock symbol is ADPT.
Adaptive Biotechnologies Prices $345 Million 0% Convertible Notes Due 2031, Adds Capped Call
Adaptive Biotechnologies has successfully priced $345 million in 0% Convertible Senior Notes due July 1, 2031. The proceeds will be used to hedge dilution through capped calls, repurchase shares, and fully retire its revenue interest obligation with OrbiMed. This move aims to streamline the company's capital structure and support its Minimum Residual Disease (MRD) growth initiatives.
Form 8K Adaptive Biotechnologies Corp For: 22 June By Investing.com
This article reports on the filing of a Form 8K by Adaptive Biotechnologies Corp (NASDAQ:ADPT) for June 22. The 8K filing is a standard requirement for publicly traded companies to announce significant events that investors should know about. No specific details about the content of the 8K are provided in this brief news item.
Insider Sell: Harlan Robins Sells 106,160 Shares of Adaptive Bio
Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (ADPT), sold 106,160 shares of the company on June 16, 2026. This transaction continues a trend of insider selling, with Robins having sold over 710,000 shares in the past year and no insider buys recorded. The stock is considered significantly overvalued based on its GF Value of $10.07, compared to its trading price of $17.41.
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock
Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold over $1.8 million worth of company common stock in two transactions on June 15 and 16, 2026, under a Rule 10b5-1 trading plan. The sales involved a total of 106,160 shares at weighted-average prices around $17.37 and $18.01, leaving Robins with 1,405,898 shares. This insider sale comes as ADPT stock has risen 60% over the past year despite being considered overvalued by InvestingPro.
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock By Investing.com
Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp, sold over $1.8 million worth of company stock across two transactions in June 2026. These sales were executed under a Rule 10b5-1 trading plan established in March 2026. Following these sales, Robins still holds a substantial stake of 1.4 million shares.
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock
Harlan S. Robins, CSO at Adaptive Biotechnologies Corp, sold shares totaling $1,847,941 in two transactions on June 15 and 16, 2026, under a Rule 10b5-1 trading plan. Following these sales, Mr. Robins still holds 1,405,898 shares. This news comes as ADPT stock is up 60% over the past year and the company reported strong Q1 2026 results, surpassing analyst expectations, and plans to separate its MRD and Immune Medicine units.
Adaptive Biotechnologies (ADPT) CSO sells 106K shares under 10b5-1 plan
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold a total of 106,160 shares of company common stock in open-market transactions on June 15 and 16, 2026. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, totaled approximately $1.85 million. Following these transactions, Robins directly holds 1,405,898 shares of ADPT common stock.
Adaptive Biotechnologies Business Separation May Unlock Greater Value
Adaptive Biotechnologies (NASDAQ: ADPT) plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to enhance value. William Blair analysts believe this move will simplify the company's investment story, provide greater flexibility for the MRD franchise, and remove a financial drag. The separation could lead to increased investor focus on the MRD business, which continues to show strong volume growth and expanding margins.
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Adaptive Biotechnologies Corporation has priced an upsized offering of $300 million in 0% convertible senior notes due 2031, increasing from the initial $250 million. The company plans to use the net proceeds to repay the OrbiMed Purchase Agreement, fund capped call transactions, repurchase $25 million of common stock, and for general corporate purposes, including opportunistic initiatives in its MRD business. The notes have an initial conversion price of $24.11 per share, representing a 40% premium over the last reported sale price of its common stock.
[144] Adaptive Biotechnologies Corp SEC Filing
Harlan Robins, associated with Adaptive Biotechnologies Corp (ADPT), reported two sales of common stock under Form 144. These transactions involved 100,000 and 10,000 shares, generating proceeds of $1,737,460 and $148,323.94, respectively. The shares were acquired as Performance Awards on March 7, 2026.
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares
Susan Bobulsky, Chief Commercial Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 5,000 shares of the company's common stock for $95,000. This transaction was part of a Rule 10b5-1 trading plan. Following the sale, Ms. Bobulsky directly holds 411,775 shares in the company.
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses
Adaptive Biotechnologies (NASDAQ: ADPT) shares rose after the company announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. The MRD segment, which focuses on diagnostics and drug development support, has shown significant growth and achieved profitability, with a projected revenue of $212 million in 2025. The company is evaluating strategic alternatives for its Immune Medicine segment to unlock shareholder value and expects to finalize the separation path by the end of 2026.
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares
Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 5,000 shares of the company's common stock for $95,000 on June 11, 2026, pursuant to a pre-arranged trading plan. This transaction leaves her with 411,775 shares. The sale follows a strong Q1 2026 financial report for Adaptive Biotechnologies, which exceeded revenue forecasts and announced plans for convertible senior notes and a business unit separation.
Adaptive Biotechnologies proposes $250M convertible notes, plans MRD/Immune Medicine separation
Adaptive Biotechnologies (ADPT) plans to offer $250 million in convertible senior notes due 2031, with proceeds used to repay debt, fund capped calls, and repurchase common stock. The company also announced its intention to separate its MRD and Immune Medicine businesses, aiming to identify a preferred path by year-end 2026. This strategic move follows reported growth in MRD revenue and leverages Immune Medicine's immune data assets for discovery.
[144] Adaptive Biotechnologies Corp SEC Filing
Harlan Robins submitted a Rule 144 notice to sell 10,000 shares of Adaptive Biotechnologies Corp (ADPT) Common Stock on April 8, 2026. The filing also details recent compensatory issuances of 47,504, 41,246, and 11,250 shares, recorded on March 7, 2026, as performance awards. This filing provides insights into insider share sales and compensation events for the company.
Executive at Adaptive Biotechnologies (ADPT) sells 5,000 shares under 10b5-1 plan
Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 5,000 shares of common stock at $19.00 per share on June 11, 2026, totaling $95,000. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Bobulsky directly holds 411,775 shares of the company.
Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD–Immune Medicine split
Adaptive Biotechnologies (NASDAQ: ADPT) plans a private offering of $250 million in convertible senior notes due 2031 to fund capped call transactions, share repurchases, and repay its OrbiMed revenue interest agreement. The company is also pursuing a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses, aiming to choose a preferred path by year-end 2026. The MRD business has shown significant growth and profitability, while the Immune Medicine business has built a large immune-receptor dataset and discovery platform.
Adaptive Biotechnologies plans $250M convertible notes offering
Adaptive Biotechnologies announced its intention to offer $250 million in convertible senior notes due 2031 through a private placement. The company plans to use the proceeds to repay the OrbiMed Purchase Agreement, fund a capped call, repurchase common stock, and support general corporate purposes and initiatives in its minimal residual disease business. Despite being unprofitable, the biotech firm has seen its stock surge 70% over the past year and recently reported stronger-than-expected Q1 2026 revenues of $70.9 million.
Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares
Adaptive Biotechnologies (ADPT) announced a private offering of $250 million convertible senior notes due 2031, with an option for an additional $37.5 million, to qualified institutional buyers. The proceeds will be used for capped call transactions, to repay the OrbiMed Purchase Agreement, fund up to $25 million in share repurchases, and for general corporate and MRD business initiatives. Following the announcement, ADPT's stock declined by 7.04%, reflecting a negative market reaction.
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Adaptive Biotechnologies Corporation announced a proposed private offering of $250 million in convertible senior notes due 2031, with an option for initial purchasers to buy an additional $37.5 million. Proceeds will be used to repay the OrbiMed Purchase Agreement, fund capped call transactions, repurchase up to $25 million of common stock, and for general corporate purposes and opportunistic initiatives in the MRD business. The notes will be unsecured senior obligations, convertible into cash, stock, or a combination, and redeemable under certain conditions.
